Evidence map›Paper›PMID 36380053›Full record

ArticleScientific reports2022

Rapid pathogen identification and phenotypic antimicrobial susceptibility directly from urine specimens.

Larry Burg, Gretel Crewe, James DiMeo, Xin Guo, Carmen G Li, Melissa Mayol, Andrew Tempesta, William Lauzier, Rachelle Markham, Katarzyna Crissy and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Point of care antimicrobial susceptibility testing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Larry BurgFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA. larry@firstlightdx.com.
Gretel CreweFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
James DiMeoFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
Xin GuoFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
Carmen G LiFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
Melissa MayolFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
Andrew TempestaFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
William LauzierFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
Rachelle MarkhamFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
Katarzyna CrissyFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
Colleen BarryFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
Bruce WalshFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.
James E KirbyBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA.
Don StrausFirst Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Funding

Rapid detection of pathogens and antimicrobial susceptibility directly in patient samplesR01AI117058 · NIAID · FIRST LIGHT DIAGNOSTICS , INC. · PI GITE, SADANAND, STRAUS, DON · 2015 to 2018
$4.2M
Rapid antimicrobial susceptibility testing directly from urine specimensR44AI157672 · NIAID · FIRST LIGHT DIAGNOSTICS , INC. · PI BURG, LAWRENCE · 2021 to 2023
$3.0M
NIAID NIH HHS R01 AI117058NIAID NIH HHS R44 AI157672U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (BARDA) #HHSO100201500022CU.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1R01AI117058-01U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) >1R44AI157672-01
6 · The paper itself

Abstract

Implementing effective antimicrobial therapy close to the onset of infection lowers morbidity and mortality and attenuates the spread of antimicrobial resistance. Current antimicrobial susceptibility testing (AST) methods, however, require several days to determine optimal therapies. We present technology and an automated platform that identify (ID) Urinary Tract Infection pathogens in 45 min and provide phenotypic AST results in less than 5 h from urine specimens without colony isolation. The ID and AST tests count cells fluorescently labeled with specific rRNA probes using non-magnified digital imaging. The ID test detected five pathogens at ≤ 7,000 CFU/mL and had a linear range of ~ 4 orders of magnitude. For contrived specimens, AST tests gave 93.1% categorical agreement with 1.3% Very Major Errors (VME), 0.3% Major Errors (ME), and 6.3% minor Errors (mE) compared to the broth microdilution (BMD) reference method. For clinical specimens, the ID test had 98.6% agreement and the AST test had 92.3% categorical agreement with 4.2% mE, 3.4% ME and 4.0% VME compared to BMD. Data presented demonstrates that direct-from-specimen AST tests can accurately determine antimicrobial susceptibility/resistance for each pathogen in a specimen containing two pathogens. The method is robust to urine matrix effects and off-target commensal and contaminating bacteria.

Indexed as

Anti-Bacterial AgentsUrinary Tract InfectionsBacteriaHumansMicrobial Sensitivity TestsAnti-Bacterial Agents

Identifiers

PMID36380053
PMCPMC9666529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.